Allelica Partners with University of Cambridge for Cancer Risk Assessment
Allelica, a pioneering precision medicine company specializing in genomic risk evaluations, has announced a strategic partnership with Cambridge Enterprise, the innovation office at the University of Cambridge. This collaboration involves licensing the BOADICEA v7 breast cancer risk prediction model, which will be integrated into Allelica's clinical risk assessment platform.
Understanding the BOADICEA Model
The BOADICEA model stands out as a highly recognized breast cancer risk assessment framework. It amalgamates rare pathogenic variants associated with high- and moderate-risk genes, polygenic risk scores, familial medical history, and various clinical risk factors. By leveraging this model, Allelica is set to enhance its commercial offerings, specifically targeting healthcare professionals for effective clinical application.
Enhancing Clinical Decision-Making
By incorporating the BOADICEA v7 model into its existing infrastructure focused on multi-ancestry polygenic risk scores, Allelica aims to provide healthcare professionals with a more thorough and clinically relevant assessment of breast cancer risk. This integration will empower clinicians to make informed decisions regarding patient management, screening, and preventative measures.
The Importance of Comprehensive Risk Assessment
According to Giordano Botta, PhD, the CEO and Co-Founder of Allelica, accurate risk assessment for breast cancer necessitates the consideration of both monogenic and polygenic genetic factors alongside well-established clinical predictors. This partnership will facilitate the merging of these varied elements into a cohesive framework that parallels the real-world evaluation of risk in clinical practice.
Clinical Validation and Utility of the BOADICEA Model
Developed by a team of researchers at the University of Cambridge, the BOADICEA model is acknowledged in clinical guidelines across various nations and is frequently utilized via the CanRisk web tool across clinical and academic frameworks worldwide. This wide array of application speaks to the model's reliability and effectiveness in risk prediction.
Allelica's Commitment to Genomic Medicine
Allelica's platform is tailored to accommodate advanced genomic risk models suitable for clinical use. It emphasizes performance across diverse ancestries while ensuring that its validation meets rigorous regulatory standards. The ultimate goal is to seamlessly integrate these advanced assessments into everyday healthcare practices.
About Allelica
Allelica is at the forefront of precision medicine, dedicated to making genomics applicable in the prevention and management of common diseases. The company specializes in developing and implementing multi-ancestry polygenic risk scores and comprehensive genetic risk models aimed at enhancing clinical care, while supporting healthcare providers and laboratories on a global scale.
About Cambridge Enterprise
Cambridge Enterprise serves as the bridge between academia and impactful innovation. It continues to leverage the research from the University of Cambridge to drive significant societal and economic benefits. By connecting researchers and innovators, it fosters the transition of groundbreaking research into practical solutions that address contemporary global challenges.
Frequently Asked Questions
What is the BOADICEA model?
The BOADICEA model is a risk prediction framework that evaluates breast cancer risk by integrating various genetic and clinical factors.
Why did Allelica license the BOADICEA model?
Allelica licensed the BOADICEA model to enhance its clinical risk assessment platform and provide comprehensive evaluations of breast cancer risk.
How does the BOADICEA model benefit clinicians?
This model allows for a more integrated approach to predicting breast cancer risk, supporting informed decisions regarding patient care.
Who developed the BOADICEA model?
The model was developed by researchers at the University of Cambridge and is widely recognized for its clinical utility.
What are Allelica's primary goals?
Allelica aims to revolutionize genomic medicine by implementing advanced risk models in clinical settings, improving patient outcomes worldwide.
